Top Markets
Coin of the day
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
Xếp hạng trong cổ phiếu #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Giá cổ phiếu
$1,133.97
Đồng bộ lần cuối: 2026-09-15
Vốn hóa thị trường
$1.068T
Thay đổi (1 ngày)
-0.39%
Thay đổi (1 năm)
48.29%
Quốc gia
US
Giao dịch Eli Lilly and Company (LLY)

Danh mục

EPS của Eli Lilly and Company (LLY)
EPS tính đến June 2026 TTM: $29.85
Theo các báo cáo tài chính mới nhất và giá cổ phiếu của Eli Lilly and Company, EPS hiện tại của công ty (TTM) là $29.85. Vào cuối năm 2024, công ty có EPS là $11.76, giảm so với EPS năm 2023 là $5.83.
Lịch sử EPS của Eli Lilly and Company từ 2000 đến 2026
EPS vào cuối mỗi năm
Năm EPS Thay đổi
2026 (TTM) $29.85 29.78%
2025 $23.00 95.58%
2024 $11.76 101.72%
2023 $5.83 -11.26%
2022 $6.57 12.31%
2021 $5.85 -9.58%
2020 $6.47 -25.55%
2019 $8.69 176.75%
2018 $3.14 -1,752.63%
2017 $-0.19 -107.63%
2016 $2.49 14.22%
2015 $2.18 1.40%
2014 $2.15 -48.69%
2013 $4.19 17.37%
2012 $3.57 -8.46%
2011 $3.90 -14.85%
2010 $4.58 16.24%
2009 $3.94 -308.47%
2008 $-1.89 -169.74%
2007 $2.71 10.61%
2006 $2.45 34.62%
2005 $1.82 8.98%
2004 $1.67 -29.83%
2003 $2.38 -5.18%
2002 $2.51 -2.71%
2001 $2.58 -8.83%
2000 $2.83 0.00%
EPS cho các công ty hoặc đối thủ cạnh tranh tương tự
Công ty EPS Chênh lệch EPS Quốc gia
$8.65 -71.02%
US
$3.55 -88.11%
US
$20.39 -31.70%
CH
$1.26 -95.78%
US
$7.19 -75.91%
CH